JPWO2021237223A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021237223A5
JPWO2021237223A5 JP2022571745A JP2022571745A JPWO2021237223A5 JP WO2021237223 A5 JPWO2021237223 A5 JP WO2021237223A5 JP 2022571745 A JP2022571745 A JP 2022571745A JP 2022571745 A JP2022571745 A JP 2022571745A JP WO2021237223 A5 JPWO2021237223 A5 JP WO2021237223A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022571745A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526975A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/033945 external-priority patent/WO2021237223A1/en
Publication of JP2023526975A publication Critical patent/JP2023526975A/ja
Publication of JPWO2021237223A5 publication Critical patent/JPWO2021237223A5/ja
Pending legal-status Critical Current

Links

JP2022571745A 2020-05-22 2021-05-24 オリゴヌクレオチド組成物及びその方法 Pending JP2023526975A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063029387P 2020-05-22 2020-05-22
US63/029,387 2020-05-22
PCT/US2021/033945 WO2021237223A1 (en) 2020-05-22 2021-05-24 Oligonucleotide compositions and methods thereof

Publications (2)

Publication Number Publication Date
JP2023526975A JP2023526975A (ja) 2023-06-26
JPWO2021237223A5 true JPWO2021237223A5 (enExample) 2024-05-31

Family

ID=78707682

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022571745A Pending JP2023526975A (ja) 2020-05-22 2021-05-24 オリゴヌクレオチド組成物及びその方法

Country Status (6)

Country Link
US (1) US20230203087A1 (enExample)
EP (1) EP4153604A4 (enExample)
JP (1) JP2023526975A (enExample)
AU (1) AU2021277407A1 (enExample)
CA (1) CA3176986A1 (enExample)
WO (1) WO2021237223A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104661664B (zh) 2012-07-13 2020-07-03 波涛生命科学有限公司 手性控制
CN113278617A (zh) 2014-01-16 2021-08-20 波涛生命科学有限公司 手性设计
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
MA45188A (fr) 2016-06-03 2019-04-10 Wave Life Sciences Ltd Oligonucléotides, compositions et méthodes associées
AU2017281497B2 (en) 2016-06-22 2023-04-06 Proqr Therapeutics Ii B.V. Single-stranded RNA-editing oligonucleotides
PL3507366T3 (pl) 2016-09-01 2021-05-04 Proqr Therapeutics Ii B.V. Chemicznie modyfikowane jednoniciowe oligonukleotydy edytujące rna
MA46905A (fr) 2016-11-23 2019-10-02 Wave Life Sciences Ltd Compositions et procédés de synthèse de phosphoramidites et d'oligonucléotides
EP3630789A4 (en) 2017-06-02 2021-06-16 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THEIR USE
CN111050806A (zh) 2017-06-02 2020-04-21 波涛生命科学有限公司 寡核苷酸组合物及其使用方法
JP7402696B2 (ja) 2017-06-21 2023-12-21 ウェイブ ライフ サイエンシズ リミテッド 合成のための化合物、組成物、及び方法
WO2019032607A1 (en) 2017-08-08 2019-02-14 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS
KR20250123934A (ko) 2017-09-18 2025-08-18 웨이브 라이프 사이언시스 리미티드 올리고뉴클레오티드 제조 기술
US11596646B2 (en) 2017-10-12 2023-03-07 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
US12391942B2 (en) 2018-05-11 2025-08-19 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
WO2023152371A1 (en) 2022-02-14 2023-08-17 Proqr Therapeutics Ii B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
WO2024013361A1 (en) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Oligonucleotides for adar-mediated rna editing and use thereof
EP4555085A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Chemically modified oligonucleotides for adar-mediated rna editing
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
WO2024110565A1 (en) 2022-11-24 2024-05-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis
GB202218090D0 (en) 2022-12-01 2023-01-18 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
CN120322556A (zh) 2022-12-09 2025-07-15 ProQR治疗上市公司Ⅱ 用于治疗心血管疾病的反义寡核苷酸
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
WO2024175550A1 (en) 2023-02-20 2024-08-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
WO2024206175A1 (en) 2023-03-24 2024-10-03 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurological disorders
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
KR20250167580A (ko) 2023-03-27 2025-12-01 프로큐알 테라퓨틱스 Ⅱ 비.브이. 간 질환 치료용 안티센스 올리고뉴클레오타이드
WO2024256620A1 (en) 2023-06-16 2024-12-19 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurodegenerative disease
WO2025051946A1 (en) 2023-09-07 2025-03-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders
WO2025070241A1 (ja) * 2023-09-25 2025-04-03 藤本化学製品株式会社 化合物又はその塩、並びにその製造方法
WO2025072886A1 (en) * 2023-09-28 2025-04-03 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
WO2025096809A1 (en) * 2023-10-31 2025-05-08 Korro Bio, Inc. Oligonucleotides comprising phosphoramidate internucleotide linkages
WO2025104239A1 (en) 2023-11-16 2025-05-22 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of classic galactosemia
WO2025132708A1 (en) 2023-12-20 2025-06-26 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of huntington's disease
WO2025151895A1 (en) * 2024-01-12 2025-07-17 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
GB202404661D0 (en) 2024-04-02 2024-05-15 Proqr Therapeutics Ii Bv Antisense oligoncleotides for the treatment of liver disease
WO2025224230A1 (en) 2024-04-25 2025-10-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of fatty liver disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216168A (en) * 1992-04-01 1993-06-01 G. D. Searle & Co. 2- and 3- amino and azido derivatives of 1,5-iminosugars
US8927513B2 (en) * 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
RU2708237C2 (ru) * 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Модифицированные олигонуклеотиды и способ их получения
IL263044B2 (en) * 2016-05-24 2024-06-01 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
WO2019200185A1 (en) * 2018-04-12 2019-10-17 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
US12391942B2 (en) * 2018-05-11 2025-08-19 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2024036694A5 (enExample)
JP2024032941A5 (enExample)
JP2025041734A5 (enExample)
JP2025069142A5 (enExample)
JP2024150466A5 (enExample)
JP2022122972A5 (enExample)
JP2024116190A5 (enExample)
JP2024114921A5 (enExample)
JPWO2021237223A5 (enExample)
JP2022184985A5 (enExample)
JP2022185040A5 (enExample)
JP2024161376A5 (enExample)
JP2024026077A5 (enExample)
JP2023116477A5 (enExample)
JP2025098156A5 (enExample)
JP2022064180A5 (enExample)
JP2020079331A5 (enExample)
JP2025094038A5 (enExample)
JP2025090801A5 (enExample)
JP2025003964A5 (enExample)
JP2024073452A5 (enExample)
JP2024149687A5 (enExample)
JP2024169680A5 (enExample)
JP2025084821A5 (enExample)
JP2024099585A5 (enExample)